292 related articles for article (PubMed ID: 25484108)
1. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
[TBL] [Abstract][Full Text] [Related]
2. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
[TBL] [Abstract][Full Text] [Related]
4. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
[TBL] [Abstract][Full Text] [Related]
5. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for the development of osteoporosis after spinal cord injury. A 12-month follow-up study.
Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2015 Sep; 26(9):2273-80. PubMed ID: 25939310
[TBL] [Abstract][Full Text] [Related]
7. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
[TBL] [Abstract][Full Text] [Related]
8. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer.
Kyvernitakis I; Rachner TD; Urbschat A; Hars O; Hofbauer LC; Hadji P
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1671-80. PubMed ID: 24903965
[TBL] [Abstract][Full Text] [Related]
9. Sclerostin levels and changes in bone metabolism after bariatric surgery.
Muschitz C; Kocijan R; Marterer C; Nia AR; Muschitz GK; Resch H; Pietschmann P
J Clin Endocrinol Metab; 2015 Mar; 100(3):891-901. PubMed ID: 25490275
[TBL] [Abstract][Full Text] [Related]
10. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
[TBL] [Abstract][Full Text] [Related]
11. Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications.
Yang CY; Chang ZF; Chau YP; Chen A; Yang WC; Yang AH; Lee OK
Nephrol Dial Transplant; 2015 Aug; 30(8):1356-63. PubMed ID: 25817223
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.
Kawazoe M; Kaneko K; Shikano K; Kusunoki N; Nanki T; Kawai S
Clin Rheumatol; 2018 Aug; 37(8):2169-2178. PubMed ID: 28551822
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
Göbel A; Kuhlmann JD; Link T; Wimberger P; Browne AJ; Rauner M; Hofbauer LC; Rachner TD
Breast Cancer Res Treat; 2017 Aug; 164(3):737-743. PubMed ID: 28526959
[TBL] [Abstract][Full Text] [Related]
14. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.
Hampson G; Edwards S; Conroy S; Blake GM; Fogelman I; Frost ML
Bone; 2013 Sep; 56(1):42-7. PubMed ID: 23702386
[TBL] [Abstract][Full Text] [Related]
15. Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis.
Morabito N; Catalano A; Gaudio A; Morini E; Bruno LM; Basile G; Tsiantouli E; Bellone F; Agostino RM; Piraino B; La Rosa MA; Salpietro C; Lasco A
J Bone Miner Metab; 2016 Sep; 34(5):540-6. PubMed ID: 26204844
[TBL] [Abstract][Full Text] [Related]
16. Changes in Serum Levels of Myokines and Wnt-Antagonists after an Ultramarathon Race.
Kerschan-Schindl K; Thalmann MM; Weiss E; Tsironi M; Föger-Samwald U; Meinhart J; Skenderi K; Pietschmann P
PLoS One; 2015; 10(7):e0132478. PubMed ID: 26147574
[TBL] [Abstract][Full Text] [Related]
17. Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine.
Kashii M; Matuso Y; Sugiura T; Fujimori T; Nagamoto Y; Makino T; Kaito T; Ebina K; Iwasaki M; Yoshikawa H
J Bone Miner Metab; 2016 May; 34(3):315-24. PubMed ID: 26040409
[TBL] [Abstract][Full Text] [Related]
18. Differences in bone mineral density, markers of bone turnover and extracellular matrix and daily life muscular activity among patients with recent motor-incomplete versus motor-complete spinal cord injury.
Kostovski E; Hjeltnes N; Eriksen EF; Kolset SO; Iversen PO
Calcif Tissue Int; 2015 Feb; 96(2):145-54. PubMed ID: 25539858
[TBL] [Abstract][Full Text] [Related]
19. Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease.
Ivanova MM; Dao J; Kasaci N; Friedman A; Noll L; Goker-Alpan O
Front Endocrinol (Lausanne); 2022; 13():1029130. PubMed ID: 36506070
[TBL] [Abstract][Full Text] [Related]
20. Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury.
Qin W; Zhao W; Li X; Peng Y; Harlow LM; Li J; Qin Y; Pan J; Wu Y; Ran L; Ke HZ; Cardozo CP; Bauman WA
Osteoporos Int; 2016 Dec; 27(12):3627-3636. PubMed ID: 27436301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
